Short Interest in Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Expands By 254.8%

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 51,800 shares, an increase of 254.8% from the February 28th total of 14,600 shares. Approximately 0.0% of the company's stock are sold short. Based on an average daily trading volume, of 85,100 shares, the short-interest ratio is presently 0.6 days.

Fresenius SE & Co. KGaA Stock Up 0.5 %

FSNUY traded up $0.05 during trading on Monday, reaching $10.92. 19,577 shares of the stock traded hands, compared to its average volume of 53,583. The stock's 50-day simple moving average is $10.16 and its two-hundred day simple moving average is $9.45. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.36 and a quick ratio of 1.05. Fresenius SE & Co. KGaA has a fifty-two week low of $6.57 and a fifty-two week high of $11.23. The stock has a market cap of $24.40 billion, a price-to-earnings ratio of 52.00 and a beta of 1.02.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.18 EPS for the quarter. The company had revenue of $6.01 billion for the quarter. As a group, equities research analysts expect that Fresenius SE & Co. KGaA will post 0.79 EPS for the current year.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Fresenius SE & Co. KGaA in a report on Monday, February 3rd.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.